Excited to announce the official launch of Braveheart Bio today. A big thank you to our investors, for the work in identifying our lead asset BHB-1893, supporting us in the Series A, and on the board. I had the privilege of working with Chris Viehbacher as the head of Biogen’s West Coast Hub, and I’m grateful he’s agreed to be part of this journey as Chair. I’m especially proud and thankful of the team we’ve put together! If you’re reading this and our story is compelling to you—we're going to be growing. You could be part of it. Keep an eye on our website for updates. https://lnkd.in/gP_PV-_3
Congratulations 👏🎉 Great timing to work on Cardiomyopathy related conditions
Sean Storms
6mo
Congrats on the launch of Braveheart! Wishing you and the team continued success as you build momentum.
Congrats
Amazing news, excited to see success!
Fantastic news, congratulations on the raise!
Uptal Patel
6mo
Congratulations Travis & team - wishing you all the best!
Wojciech Gryc
6mo
Congratulations! This is awesome!
Outstanding milestone for cardiovascular innovation — Congratulations to the Braveheart Bio team and investors. BHB-1893 appears to be one of the most promising next-generation myosin inhibitors in HCM, combining a rapid onset of action with a clean exposure–response and practical dosing profile. It’s encouraging to see a leadership group with such deep translational and late-stage development expertise taking this molecule global. The cardiovascular space has long needed differentiated assets that improve patient outcomes and quality of life beyond current therapies, and Braveheart’s focused approach in both obstructive and non-obstructive HCM could set a new benchmark. Exciting to watch how this program progresses toward Phase 3 and potential regulatory engagement in 2026.